Astrocytoma

P1/2, N=40, Recruiting, National Institute of Neurological Disorders and Stroke (NINDS) | Not yet recruiting --> Recruiting

The presence of a hemizygous CDKN2A/B deletion occurs more frequently in astrocytomas compared to oligodendrogliomas at the time of primary diagnosis. Worse survival in patients with astrocytoma and CDKN2A/B hemizygous loss was observed, specifically in WHO grade 2, but this prognostic effect disappeared when adjusting for clinical factors.

Together, our results show that expression of the GFAP R239C AxD mutant is sufficient to deeply perturb lysosomal distribution, function and repair. These alterations could contribute to proteostasis defects and cellular toxicity in AxD.

Because BRAF alterations are observed in most pilocytic astrocytomas, treatments targeting the MAPK pathway play an important role in the management of optic gliomas. Inhibition of the MAPK signaling pathway represents a potential advance in the treatment of optic gliomas.

P1, N=83, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027

There was no correlation of LAT1 or CD98hc expression with amino acid PET uptake parameters. Further studies to clarify the molecular basis of amino acid tracer uptake in diffuse glioma are warranted.

P1, N=24, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting

These findings suggest additional molecular alterations associated with tumor progression within the piloid lineage. To our knowledge, this is the first report providing comprehensive, paired molecular characterization of both PA and HGAP in the same patient, offering insight into their potential evolutionary relationship.

P4, N=165, Recruiting, Novartis Pharmaceuticals | Active, not recruiting --> Recruiting

Adult IDH-mutant BSGs represent a clinically meaningful subgroup with outcomes more favorable than H3K27-altered gliomas but shorter than supratentorial IDH-mutant gliomas. Their recurrent molecular features, including frequent non-canonical IDH variants, warrant study in larger cohorts to clarify biological significance, refine prognostication, and inform the potential role of IDH-targeted therapies.

Our work presents a detailed analysis of a large series of IDH-mutant astrocytomas, underscoring the prognostic importance of WHO grade 4, tumor volume, and EOR.

This study demonstrates that increased expression of autophagy-related genes, particularly SQSTM1 and Beclin1, serves as a robust indicator of poor prognosis and shorter survival times in diffuse astrocytic tumors. Furthermore, the elevated expression of Beclin1 and Atg5 in IDH-mutant cases highlights a complex metabolic interplay that warrants further investigation as potential therapeutic targets.